Description:
Adalimumab is the first fully human recombinant immunoglobulin G1 (IgG1) anti-TNF monoclonal antibody. Adalimumab is currently indicated for reducing the signs and symptoms, inducing major clinical response, inhibiting the progression of joint damage, and improving physical function in adult patients with moderately to severely active RA.
Adalimumab exerts its therapeutic effects by blocking the interaction of TNF with the p55 and p75 cell surface TNF receptors. Adalimumab is also known for downregulation of serum matrix metalloproteinase (MMP)-1 and MMP-3 and attenuate cartilage and bone destruction. Adalimumab is mostly preferred in combination with methotrexate/csDMARDs in case of inadequate response to one or more csDMARDs.
Share your experience with our medical product. Write a review!
22 Jul 2026
International Yoga Day 2026: How Yoga Promotes Wellness, Wisdom & Inner Peace
Yoga is more than a form of physical exercise. It is a holistic practice that connects the body, mind, and breath to support overall wellbeing. Every year, International Yoga Day encourages people aro
15 Jul 2026
World Brain Tumor Day 2026: Early Detection Awareness and the Need to Reduce Diagnostic Delays
World Brain Tumor Day is observed annually on 8 June to raise awareness about brain tumours, encourage early diagnosis, and support patients and families affected by these complex conditions.
15 Jun 2026
Hetero Healthcare on World No Tobacco Day 2026 - Unmasking the Appeal, Countering Addiction
Every year on May 31, the world comes together to observe World No Tobacco Day, a global initiative aimed at raising awareness about the dangers of tobacco use.
01 Jun 2026
Salt, Stress, and Sedentary Life: The Three Big Triggers of Hypertension
Every two seconds, somewhere in the world, a person suffers a heart attack or stroke linked to uncontrolled blood pressure.
